*New

The F01A study section reviews fellowship applications with an emphasis on clinical neuroscience and disease. The science proposed may investigate aspects of neuroplasticity, neurodegeneration, neuroimmunology, developmental brain disorders, TBI, stroke and autism. They may often employ clinical symptomology, behavioral, brain imaging, electrophysiological recording and stimulation, deep brain stimulation or computational modeling, but may also utilize cellular/molecular approaches, including genetic or epigenetic methods. Studies may focus on the underlying mechanisms of a disorder or potential therapeutics. While animal models may be used occasionally, F01A study section predominantly reviews fellowship applications with a clinical emphasis.

The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Topics


  • Therapeutic treatments for brain injury and diseases including neuroprotection, immuno-therapeutics, cell transplantation, nanotechnology and deep brain stimulation
  • In vivo neuroplasticity and neuroprotection studies related to epilepsy and other brain diseases
  • Therapeutic strategies to enhance recovery of function after spinal cord injury, stroke, ischemia and traumatic brain injury
  • In vivo studies of mechanisms underlying autism, schizophrenia, depression and bipolar disorders
  • Therapeutic approaches for behavioral, cognitive and emotional disorders
  • In vivo analysis of mechanisms and therapeutics for central nervous system tumors
  • Behavioral, cognitive, emotional and biological factors involved in the etiology of disorders
  • Diagnosis, nosology, course and outcome of neurological and mental disorders
  • Behavioral and pharmacological interventions/treatments; adherence to behavioral and pharmacologic treatments
  • Alzheimer’s Disease and Related Dementias (ADRD), and other neurodegenerative diseases (e.g., Parkinson’s and Huntington’s diseases, etc) when the focus is on clinical, behavioral and cognitive outcomes, primarily in human subjects.
  • Disorders of cognitive, sensory, perceptual and motor development, including intellectual disabilities, autism, and attention deficit hyperactivity disorder when the focus is on clinical and cognitive outcomes.
  • Clinical treatment approaches to substance use disorders.

 

Last updated: 09/22/2025 14:36